AU716204B2 - Novel erythromycin derivatives, method for preparing same, and use thereof as drugs - Google Patents

Novel erythromycin derivatives, method for preparing same, and use thereof as drugs

Info

Publication number
AU716204B2
AU716204B2 AU19298/97A AU1929897A AU716204B2 AU 716204 B2 AU716204 B2 AU 716204B2 AU 19298/97 A AU19298/97 A AU 19298/97A AU 1929897 A AU1929897 A AU 1929897A AU 716204 B2 AU716204 B2 AU 716204B2
Authority
AU
Australia
Prior art keywords
radical
product
formula
drugs
erythromycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU19298/97A
Other languages
English (en)
Other versions
AU1929897A (en
Inventor
Constantin Agouridas
Jean-Francois Chantot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Hoechst Marion Roussel
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel, Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel
Publication of AU1929897A publication Critical patent/AU1929897A/en
Application granted granted Critical
Publication of AU716204B2 publication Critical patent/AU716204B2/en
Assigned to AVENTIS PHARMA S.A. reassignment AVENTIS PHARMA S.A. Alteration of Name(s) in Register under S187 Assignors: HOECHST MARION ROUSSEL
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU19298/97A 1996-02-28 1997-02-27 Novel erythromycin derivatives, method for preparing same, and use thereof as drugs Expired AU716204B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9602472A FR2745290B1 (fr) 1996-02-28 1996-02-28 Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR96/02472 1996-02-28
PCT/FR1997/000351 WO1997031929A1 (fr) 1996-02-28 1997-02-27 Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments

Publications (2)

Publication Number Publication Date
AU1929897A AU1929897A (en) 1997-09-16
AU716204B2 true AU716204B2 (en) 2000-02-24

Family

ID=9489659

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19298/97A Expired AU716204B2 (en) 1996-02-28 1997-02-27 Novel erythromycin derivatives, method for preparing same, and use thereof as drugs

Country Status (31)

Country Link
US (1) US6096714A (enExample)
EP (1) EP0885234B1 (enExample)
JP (1) JP4102440B2 (enExample)
KR (1) KR100486053B1 (enExample)
CN (1) CN1168734C (enExample)
AP (1) AP952A (enExample)
AR (1) AR005999A1 (enExample)
AT (1) ATE217633T1 (enExample)
AU (1) AU716204B2 (enExample)
BG (1) BG63207B1 (enExample)
BR (1) BR9707709B1 (enExample)
CZ (1) CZ293893B6 (enExample)
DE (1) DE69712610T2 (enExample)
DK (1) DK0885234T3 (enExample)
EA (1) EA001376B1 (enExample)
EE (1) EE9800265A (enExample)
ES (1) ES2176698T3 (enExample)
FR (1) FR2745290B1 (enExample)
HU (1) HU227567B1 (enExample)
IL (1) IL125622A (enExample)
NO (1) NO983955L (enExample)
NZ (1) NZ331600A (enExample)
OA (1) OA10845A (enExample)
PL (1) PL191736B1 (enExample)
PT (1) PT885234E (enExample)
SK (1) SK118498A3 (enExample)
TR (1) TR199801713T2 (enExample)
UA (1) UA58504C2 (enExample)
WO (1) WO1997031929A1 (enExample)
YU (1) YU37098A (enExample)
ZA (1) ZA971659B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004514643A (ja) * 1997-10-29 2004-05-20 大正製薬株式会社 エリスロマイシンａ誘導体
WO1999021869A1 (en) * 1997-10-29 1999-05-06 Taisho Pharmaceutical Co., Ltd. Erythromycin a, 11,12-carbamate derivatives
FR2780977B1 (fr) * 1998-07-09 2000-09-01 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
JP4573925B2 (ja) * 1998-07-09 2010-11-04 アベンティス・ファーマ・ソシエテ・アノニム 新規のエリスロマイシン誘導体、その製造方法及びその薬剤としての使用
FR2792637B1 (fr) * 1999-04-26 2001-06-01 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2781484B1 (fr) * 1998-07-21 2001-08-10 Hoechst Marion Roussel Inc Nouveaux derives de la 6-deoxy erythromycine, leur procede de preparation et leur application comme medicaments
DK1147121T3 (da) 1999-01-27 2004-04-13 Pfizer Prod Inc Ketolidantibiotika
EE200100613A (et) * 1999-05-24 2003-02-17 Pfizer Products Inc. 13-metüülerütromütsiini derivaadid
AU6183800A (en) * 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
WO2001010878A1 (fr) * 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
AU6316400A (en) * 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
EP1146051A3 (en) * 2000-04-10 2001-10-31 Pfizer Products Inc. Erythromycin A derivatives
US20020115621A1 (en) * 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
ITMI20021726A1 (it) * 2002-08-01 2004-02-02 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
WO2005007143A2 (en) * 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Use of makrolides and ketolides for the treatment of tuberculosis
WO2007069264A2 (en) * 2005-12-15 2007-06-21 Alembic Limited Reference standards for determining the purity of telithromycin and processes therefor
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
CN107854477A (zh) 2008-10-24 2018-03-30 森普拉制药公司 使用含三唑的大环内酯治疗抗性疾病的方法
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
HRP20160168T1 (hr) 2010-03-22 2016-03-25 Cempra Pharmaceuticals Inc Kristalne forme makrolida i njihova uporaba
BR112012029586A2 (pt) 2010-05-20 2016-08-02 Cempra Pharmaceuticals Inc processos para preparar macrolídeos e cetolídeos e intermediários dos mesmos
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
WO2014152326A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
AU2014233240B2 (en) 2013-03-15 2018-08-09 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US487411A (en) * 1892-12-06 Island
AU4032495A (en) * 1994-12-09 1996-06-20 Aventis Pharma S.A. New erythromycin derivatives, their preparation process and their use as medicaments

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99995A (en) * 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5444031A (en) * 1993-01-21 1995-08-22 Calgon Carbon Corporation Process for making catalytic carbon

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US487411A (en) * 1892-12-06 Island
AU4032495A (en) * 1994-12-09 1996-06-20 Aventis Pharma S.A. New erythromycin derivatives, their preparation process and their use as medicaments

Also Published As

Publication number Publication date
BG63207B1 (bg) 2001-06-29
PT885234E (pt) 2002-10-31
KR19990087324A (ko) 1999-12-27
NZ331600A (en) 1999-08-30
EP0885234A1 (fr) 1998-12-23
HU227567B1 (en) 2011-08-29
EA001376B1 (ru) 2001-02-26
AP952A (en) 2001-03-29
CZ293893B6 (cs) 2004-08-18
HUP9902576A1 (hu) 1999-12-28
JP4102440B2 (ja) 2008-06-18
SK118498A3 (en) 1999-07-12
FR2745290A1 (fr) 1997-08-29
HUP9902576A3 (en) 2001-03-28
PL191736B1 (pl) 2006-06-30
CZ258798A3 (cs) 1998-12-16
DE69712610D1 (de) 2002-06-20
AU1929897A (en) 1997-09-16
ATE217633T1 (de) 2002-06-15
BG102691A (en) 1999-06-30
AR005999A1 (es) 1999-07-21
CN1168734C (zh) 2004-09-29
US6096714A (en) 2000-08-01
KR100486053B1 (ko) 2005-06-16
TR199801713T2 (xx) 1998-12-21
IL125622A0 (en) 1999-04-11
DK0885234T3 (da) 2002-08-26
WO1997031929A1 (fr) 1997-09-04
DE69712610T2 (de) 2002-11-28
EE9800265A (et) 1999-02-15
UA58504C2 (uk) 2003-08-15
FR2745290B1 (fr) 1998-04-03
IL125622A (en) 2003-10-31
EP0885234B1 (fr) 2002-05-15
ES2176698T3 (es) 2002-12-01
NO983955D0 (no) 1998-08-27
YU37098A (sh) 1999-07-28
OA10845A (fr) 2003-02-05
CN1212700A (zh) 1999-03-31
AP9801318A0 (en) 1998-09-30
JP2000505469A (ja) 2000-05-09
EA199800768A1 (ru) 1999-02-25
ZA971659B (en) 1998-02-26
BR9707709B1 (pt) 2014-10-14
BR9707709A (pt) 1999-04-06
NO983955L (no) 1998-08-27
PL328608A1 (en) 1999-02-01

Similar Documents

Publication Publication Date Title
AP952A (en) Novel erthromycin derivatives, method for preparing same, and use thereof as drugs.
AU697876B2 (en) New erythromycin derivatives, their preparation process and their use as medicaments
US6433151B1 (en) Erythromycin derivatives, a process for their preparation and their use as medicaments
AU721732B2 (en) New derivatives of erythromycin, their preparation process and their use as medicaments
JP5188520B2 (ja) 新規なエリスロマイシン誘導体、製造方法及び医薬としての利用
AP1078A (en) Novel erythromycin derivatives, method for preparing same and use thereof as drugs.
JP4864184B2 (ja) ５−デスオサミニルエリスロノリドａの新規の２−ハロゲン化誘導体、それらの製造方法及び薬剤としてのそれらの使用
USRE38520E1 (en) Erythromycin derivatives, method for preparing same, and use thereof as drugs
AU761551B2 (en) Novel 6-deoxy erythromycin derivatives, method for preparing same and use as medicines
MXPA99005840A (en) Novel erythromycin derivatives, method of preparation and application as medicines
MXPA99005226A (en) Novel erythromycin derivatives, method for preparing them and their use as medicine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: AVENTIS PHARMA S.A.

Free format text: FORMER OWNER WAS: HOECHST MARION ROUSSEL